AIMD.P AIM4 Ventures

Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020

Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020

BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET.

Investors interested in viewing Annovis Bio's presentation may register with free access  for the two-day conference which takes place virtually from December 8-9, 2020.

During the presentation, Dr. Maccecchini will discuss the Company’s unique approach to AD and other neurodegenerative diseases, current pipeline, and upcoming milestones, including expected publication of data from its current Phase 2a studies in AD and PD.

About Benzinga

Benzinga is a leading financial media company dedicated to making information easier to consume. Benzinga's news desk is constantly breaking stories and moving billions of dollars of market capitalization through its real-time news tool, Benzinga Pro. Benzinga's original content is syndicated to 70 partner websites including Yahoo! Finance MSN, CNNMoney, Fox Business and MarketWatch.

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company’s website: .

Investor Relations:

Dave Gentry, CEO

RedChip Companies Inc.

407-491-4498

SOURCE: Annovis Bio, Inc.



EN
07/12/2020

Underlying

AIMD.PAIM4 Ventures

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM4 Ventures

 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces Closing of $6 Million Registered Direct Offering of ...

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per...

October 15, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces $6 Million Registered Direct Offering of Common Stoc...

Annovis Announces $6 Million Registered Direct Offering of Common Stock MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant i...

October 10, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Support...

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifyin...

October 9, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Appoints Mark Guerin as Chief Financial Officer

Annovis Appoints Mark Guerin as Chief Financial Officer MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experien...

September 25, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetic...

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of a new article in a peer-reviewed journal , which describes the pharmacokinetic (PK) profile of a new crystal form of buntanetap and compares it to the old form across several s...

September 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch